The DOI matches its Crossref record.
The Physicochemical Challenges of Designing Multiple Ligands
Abstract
Compounds designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands. The physicochemical properties of designed multiple ligands were found to be less druglike than those for preclinical compounds in general. These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed. The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike. The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values. Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized. For some target combinations, a screening approach may provide a route to smaller, less complex leads.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Filimonov, D. A., Lagunin, A. A., Gloriozova, T. A., Rudik, A. V., Druzhilovskii, D. S., Pogodin, P. V., & Poroikov, V. V. (2014) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-014-1496-1 · Cited by 1,346
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 375
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Self-citationRational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
Lagorce, D., Douguet, D., Miteva, M. A., & Villoutreix, B. O. (2017) · Scientific Reports · doi:10.1038/srep46277 · Cited by 266
Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 260
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110
Prati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110
Potter, B. V. L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0045 · Cited by 73
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Steroid sulphatase and its inhibitors: past, present, and future
Foster, P. A. (2021) · Molecules · doi:10.3390/molecules26102852 · Cited by 49
Metadata
- Authors
- Morphy, R., & Rankovic, Z.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-07-15
- Volume
- 49
- Issue
- 16
- Pages
- 4961-4970
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2074593965
- Cited by
- 194
- References
- 0
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.